Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Clinical PsychopharmacologyOpen Access

Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression

View Full Paper
Ask AI
Bookmark
Share

Authors

RARenee E. AlbersMDM DyerMKMatthew Kucera

Discussion

Loading...

Member takes

Overview

Meta-analysis shows improved response and remission rates in adults with major depressive disorder via pharmacogenomic testing.

Key Points

  • Patients with MDD receiving PGx-guided care experienced a 30% increase in response rates compared to unguided care.
  • There was a 41% improvement in remission rates for patients with MDD whose treatment was guided by the weighted multigene PGx test.
  • The analysis incorporated six prospective studies, ensuring a focused evaluation of this specific multigene test's effectiveness.
  • Results indicated no variations in outcomes across the included studies, supporting the reliability of the findings.

Cite This Study

Albers et al. (2025) studied this question.

synapsesocial.com/papers/68c23b4ab210217d64784c5bhttps://doi.org/10.1097/jcp.0000000000002061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses2025 · 9 citations
  2. 2Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review2025 · 3 citations
  3. 3Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis2025 · 5 citations
  4. 4Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study2025
  5. 5177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025